-
新药9401是以烟酰胺为母体化合物合成的烟酰氨基酸类化合物,是中国医学科学院放射医学研究所自行设计、合成、研制的国家一类创新药物。该药物具有毒性低,辐射增敏效果明显等特点。体外实验结果表明,9401辐射增敏效果比目前临床试用的母体化合物烟酰胺好,且毒性低[1],是目前很有希望成为肿瘤放疗高效、低毒而有实用前景的放射增敏剂。本研究以荷H22肝癌小鼠为实验对象,探讨9401对延缓肿瘤生长时间和抑制肿瘤生长的作用及在体内的放射增敏作用。
-
各组肿瘤生长的延缓时间和辐射增敏系数见表 1。结果表明,9401高、中、低各剂量联合照射组均能延缓肿瘤生长,与单纯照射组相比,差异有统计学意义(t=40.1,26.0和9.7,P均<0.01);9401高、中剂量联合照射组与烟酰胺联合照射组相比,肿瘤生长延缓时间差异有统计学意义(t=24.7和7.5,P均<0.01);且9401高、中剂量组辐射敏感性均显著增高,增敏系数分别为2.13、1.73,明显高于烟酰胺联合照射组的增敏系数1.61,差异有统计学意义(t=2.26和9.04,P均<0.05);9401低剂量联合照射组的增敏效果低于烟酰胺联合照射组,差异有统计学意义(t=18.6,P < 0.01)。
组别 只数 肿瘤生长天数(x±s,d) 肿瘤生长的延缓天数(d) 辐射增敏系数 空白对照组 8 7.5±0.75 - - 单纯照射组 8 15.4±0.73 8.9 - 烟酰胺联合照射组 8 21.8±0.19 14.3 1.61 9401低剂量联合照射组 8 18.4±0.48 10.9 1.22 9401中剂量联合照射组 8 22.9±0.36 15.4 1.73 9401高剂量联合照射组 8 26.5±0.25 19.0 2.13 注:表中,“-”表示无数据。 表 1 各组H22肝癌小鼠肿瘤生长的延缓时间和辐射增敏系数
-
9401高、中、低各剂量联合照射组均能抑制肿瘤生长,抑制肿瘤作用随给药剂量的增加而逐渐增强。9401高、中、低各剂量联合照射组的抑瘤率分别为64.5%、50.9%、42.6%,烟酰胺联合照射组的抑瘤率为53.2%,9401高剂量联合照射组抑瘤效果显著高于烟酰胺联合照射组,差异有统计学意义(t=2.8,P < 0.05)。9401高、中、低各剂量联合照射组与单纯照射组比较,差异有统计学意义(t=5.7,4.0和2.2,P均<0.05)(表 2)。
组别 只数 瘤重(x±s,g) 抑瘤质量(x±s,g) 抑瘤率(%) 空白对照组 8 1.044±0.209 - - 单纯照射组 8 0.740±0.108 0.304±0.101 29.1 烟酰胺联合照射组 8 0.489±0.136 0.555±0.073 53.2 9401低剂量联合照射组 8 0.599±0.141 0.445±0.068 42.6 9401中剂量联合照射组 8 0.513±0.117 0.531±0.092 50.9 9401高剂量联合照射组 8 0.371±0.149 0.673±0.060 64.5 注:表中,“-”表示无数据。 表 2 各组H22肝癌小鼠肿瘤瘤重及抑瘤率
9401对H22肝癌小鼠放射增敏效应的研究
Radiosensitizing effects of 9401 on mice bearing H22 hepatoma
-
摘要:
目的 探讨9401对H22肝癌小鼠的放射增敏作用。 方法 建立H22肝癌小鼠模型,按照给药和照射的不同,分为空白对照组、单纯照射组、烟酰胺联合照射组、9401高剂量联合照射组、9401中剂量联合照射组和9401低剂量联合照射组。照射后观察H22肝癌小鼠的肿瘤生长情况、记录肿瘤照射后的生长时间,并计算肿瘤生长的延迟时间和各组的放射增敏系数。照射后28 d处死小鼠,剥瘤称重,计算抑瘤率。 结果 9401高、中、低各剂量联合照射组均能延缓肿瘤生长,其中9401高、中剂量联合照射组与烟酰胺联合照射组相比,差异有统计学意义(t=24.7和7.5,P均<0.01),且9401高、中剂量组辐射敏感性均显著增高,增敏系数分别为2.13、1.73,明显高于烟酰胺联合照射组的增敏系数1.61,差异有统计学意义(t=2.26和9.04,P均<0.05);9401高、中、低各剂量联合照射组的抑瘤率分别为64.5%、50.9%、42.6%,烟酰胺联合照射组的抑瘤率为53.2%,9401高剂量组抑瘤效果显著高于烟酰胺联合照射组,差异有统计学意义(t=2.8,P < 0.05)。9401高、中、低各剂量组与单纯照射组相比,抑瘤率差异有统计学意义(t=5.7,4.0和2.2,P均<0.05)。 结论 9401对H22肝癌小鼠肿瘤生长有明显的抑制作用,抑制肿瘤作用随给药剂量的增加而逐步增强,放射增敏效果显著,临床应用前景广阔。 Abstract:Objective To investigate the radiosensitizing effects of 9401 on mice bearing H22 hepatoma. Methods Mouse model bearing H22 hepatoma cells were established. Mice were randomly divided into six groups, the control group, the radiation group and four treatment groups including 9401 at high, medium and low dosages and nicotinamide combined with radiation. After irradiated, the growth of tumor was observed, the time of tumor growth was recorded, the delay time of tumor growth and enhancement factor(EF)were calculated. After 28 days, the mice were killed, the tumors were stripped and inhibition rate was calculated. Results Groups of 9401 combined with radiation could pestpone tumor growth. The difference was statistically significant between 9401 groups at high, medium dosages combined with radiation and nicotinamide combined with radiation group (t=24.7 and 7.5, both P < 0.01). Compared with radiation alone group, groups of 9401 combined with radiation had significant radiosensitizing effect. The enhancement factor of 9401 combined with radiation groups at high and medium dosages were 2.13 and 1.73 respectively, they were significant higher than nicotinamide combined with radiation group(t=2.26 and 9.04, both P < 0.05). The inhibition rate of 9401 groups at high, medium and low dosages combined with radiation were 64.5%, 50.9% and 42.6% respectively. The inhibition rate of nicotinamide group combined radiation was 53.2%. The inhibition rate of 9401 at high dosage combined with radiation had significant difference with nicotinamide combined radiation(t=2.8, P < 0.05). Nicotinamide combined with radiation group, 9401 combined with radiation groups could significant inhibit the growth of tumors compared with radiation alone group(t=5.7, 4.0 and 2.2, all P < 0.05). Conclusion 9401 can inhibit the tumor growth and the inhibition effect increases gradually with the drug dose increasing. It also has radiosensitizing effects on mice bearing H22 hepatoma and present broadly clinical practice prospect. -
Key words:
- Hepatoma /
- Radiation-sensitizing agents /
- Dose-response relationship /
- drug /
- Model /
- animal /
- Mice
-
表 1 各组H22肝癌小鼠肿瘤生长的延缓时间和辐射增敏系数
组别 只数 肿瘤生长天数(x±s,d) 肿瘤生长的延缓天数(d) 辐射增敏系数 空白对照组 8 7.5±0.75 - - 单纯照射组 8 15.4±0.73 8.9 - 烟酰胺联合照射组 8 21.8±0.19 14.3 1.61 9401低剂量联合照射组 8 18.4±0.48 10.9 1.22 9401中剂量联合照射组 8 22.9±0.36 15.4 1.73 9401高剂量联合照射组 8 26.5±0.25 19.0 2.13 注:表中,“-”表示无数据。 表 2 各组H22肝癌小鼠肿瘤瘤重及抑瘤率
组别 只数 瘤重(x±s,g) 抑瘤质量(x±s,g) 抑瘤率(%) 空白对照组 8 1.044±0.209 - - 单纯照射组 8 0.740±0.108 0.304±0.101 29.1 烟酰胺联合照射组 8 0.489±0.136 0.555±0.073 53.2 9401低剂量联合照射组 8 0.599±0.141 0.445±0.068 42.6 9401中剂量联合照射组 8 0.513±0.117 0.531±0.092 50.9 9401高剂量联合照射组 8 0.371±0.149 0.673±0.060 64.5 注:表中,“-”表示无数据。 -
[1] Demuth I, Digweed M. T The clinical manifestation of a defective response to DNA double-strand breaks as exemplified by Nijmegen breakage syndrome. Oncogene, 2007, 26(56): 7792-7798. doi: 10.1038/sj.onc.1210876 [2] Yano K, Morotomi-Yano K, Adachi N, et al. Molecular mechanism of protein assembly on DNA double-strand breaks in the non-homologous end-joining pathway. J Radiat Res, 2009, 50(2): 97-108. doi: 10.1269/jrr.08119 [3] Liu Y, Tarsounas M, O'regan P, et al. Role of RAD51C and XRCC3 in genetic recombination and DNA repair. J Biol Chem, 2007, 282(3): 1973-1979. doi: 10.1074/jbc.M609066200 [4] 杨青山,樊飞跃. Ku蛋白与DNA修复. 国际放射医学核医学杂志,2008,32(1): 40-43.
[5] 程晋. DNA损伤修复及细胞周期检控点激活的研究进展. 国际放射医学核医学杂志, 2009, 33(6): 360-364.
[6] Roberts SA, Ramsden DA. Loading of the nonhomologous end joining factor, Ku, on protein-occluded DNA ends. J Biol Chem, 2007, 282(14): 10605-10613. doi: 10.1074/jbc.M611125200 [7] Mari PO, Florea BI, Persengiev SP, et al. Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci USA, 2006,103(49): 18597-18602. doi: 10.1073/pnas.0609061103 [8] Evans JW, Liu XF, Kirchgessner CU, et al. Induction and repair of chromosome aberrations in scid cells measured by premature chromosome condensation. Radiat Res, 1996, 145(1): 39-46. doi: 10.2307/3579193 [9] Simsek D, Jasin M. Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4-ligase IV during chromosomal translocation formation. Nat Struct Mol Biol, 2010, 17(4): 410-416. doi: 10.1038/nsmb.1773 [10] Nasiri M, Saadat I, Omidvari S, et al. Genetic variation in DNA repair gene XRCC7(G6721T) and susceptibility to breast cancer. Gene, 2012, 505(1): 195-197. doi: 10.1016/j.gene.2012.04.065 [11] Shammas MA, Shmookler Reis RJ, Koley H, et al. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood, 2009, 113(10): 2290-2297. doi: 10.1182/blood-2007-05-089193 [12] Kuznetsov SG, Haines DC, Martin BK, et al. Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice. Cancer Res, 2009, 69(3): 863-872. doi: 10.1158/0008-5472.CAN-08-3057 [13] 王芹. X射线修复交叉互补基因功能的研究进展. 国外医学放射医学核医学分册, 2005, 29(3): 132-136.
[14] Tambini CE, Spink KG, Ross CJ, et al. The importance of XRCC2 in RAD51-related DNA damage repair. DNA Repair (Amst), 2010, 9(5): 517-525. doi: 10.1016/j.dnarep.2010.01.016 [15] Johnson RD, Liu N, Jasin M. Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. Nature, 1999, 401(6751): 397-399. [16] 张占春. 电离辐射损伤与DNA修复基因. 国外医学放射医学核医学分册,2004,28(1): 26-29 .
[17] Fan S, Meng Q, Auborn K, et al. BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer, 2006, 94(3): 407-426. doi: 10.1038/sj.bjc.6602935